T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Eton Pharmaceutcials
ETON
$1.12B
| $260K | ﹤0.01% |
15,369
+1,845
| +14% | +$32.5K |
|
|
TBI
2702
Trueblue
TBI
$309M
| $260K | ﹤0.01% |
56,959
+6,400
| +13% | +$32.8K |
|
2703
First Business Financial Services
FBIZ
$601M
| $259K | ﹤0.01% |
4,768
+586
| +14% | +$30.6K |
|
2704
Caledonia Mining Corp
CMCL
$439M
| $258K | ﹤0.01% |
9,856
+1,078
| +12% | +$31.7K |
|
|
STRS
2705
DELISTED
STRATUS PPTYS INC
STRS
| $258K | ﹤0.01% |
10,631
| – | – |
|
2706
American Battery Technology Co
ABAT
$342M
| $254K | ﹤0.01% |
75,885
+24,299
| +47% | +$114K |
|
2707
Civista Bancshares
CIVB
$595M
| $254K | ﹤0.01% |
11,423
+1,227
| +12% | +$27.1K |
|
2708
Choiceone Financial
COFS
$515M
| $254K | ﹤0.01% |
8,578
+1,041
| +14% | +$30.8K |
|
2709
Playtika
PLTK
$961M
| $254K | ﹤0.01% |
64,275
-42,257
| -40% | -$165K |
|
|
AEVA
2710
Aeva Technologies
AEVA
$1.56B
| $253K | ﹤0.01% |
19,007
+2,961
| +18% | +$42.2K |
|
2711
Kosmos Energy
KOS
$1.51B
| $253K | ﹤0.01% |
280,365
-108,630
| -28% | -$143K |
|
|
MH
2712
McGraw Hill
MH
$2.6B
| $253K | ﹤0.01% |
15,306
+2,743
| +22% | +$39.8K |
|
2713
Columbia Financial
CLBK
$1.22B
| $251K | ﹤0.01% |
16,106
+1,704
| +12% | +$26.4K |
|
2714
Marcus Corp
MCS
$929M
| $250K | ﹤0.01% |
16,107
+2,336
| +17% | +$34.7K |
|
2715
Quad
QUAD
$506M
| $250K | ﹤0.01% |
39,794
| – | – |
|
2716
Smith & Wesson
SWBI
$643M
| $250K | ﹤0.01% |
25,253
+2,093
| +9% | +$20.2K |
|
2717
Lightbridge
LTBR
$327M
| $249K | ﹤0.01% |
19,682
+7,444
| +61% | +$143K |
|
2718
Miller Industries
MLR
$640M
| $249K | ﹤0.01% |
6,637
+768
| +13% | +$29.9K |
|
2719
Sierra Bancorp
BSRR
$532M
| $247K | ﹤0.01% |
+7,536
| New | +$228K |
|
|
DHIL
2720
DELISTED
Diamond Hill
DHIL
| $247K | ﹤0.01% |
1,453
| – | – |
|
2721
Mesa Laboratories
MLAB
$633M
| $247K | ﹤0.01% |
3,141
-972
| -24% | -$73.9K |
|
|
LBRX
2722
LB Pharmaceuticals
LBRX
$1.43B
| $247K | ﹤0.01% |
11,074
-271,570
| -96% | -$4.74M |
|
2723
Medifast
MED
$128M
| $245K | ﹤0.01% |
22,905
+4,500
| +24% | +$53.8K |
|
2724
Pangaea Logistics
PANL
$496M
| $245K | ﹤0.01% |
35,472
| – | – |
|
2725
Southern California Bancorp
BCAL
$699M
| $243K | ﹤0.01% |
12,988
+978
| +8% | +$18K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.